Literature DB >> 28340210

Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia.

Matthew J Oberley1,2, Sisi Li3, Etan Orgel4, Choo Phei Wee5, Ashley Hagiya2, Maurice R G O'Gorman1,2.   

Abstract

Objectives: Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) requires immunophenotypic evidence of B-lineage and absence of specific myeloid or T-lineage markers. Rare cases of otherwise typical B-ALL express myeloperoxidase (MPO) detectable by flow cytometry with an absence of other myeloid markers, but the clinical significance of this finding is not well studied.
Methods: A retrospective cohort analysis of flow cytometry and clinical data was performed to investigate the clinical outcome of this specific group of patients.
Results: Twenty-nine cases of otherwise typical B-ALL that expressed MPO by flow cytometry (B-ALL-isoMPO) without expression of other myeloid markers were identified. The B-ALL-isoMPO group had a significantly increased incidence of relapse (univariate log rank P  = .0083; multivariate hazard ratio, 2.50; 95% confidence interval, 1.07-5.85; P  = .034) and significantly worse event-free survival by univariate analysis (log rank P  = .0066) compared with a reference group of patients with B-ALL from the same time period (n = 264). Conclusions: To our knowledge, this is the first report to document the clinical outcomes in a group of pediatric patients with B-ALL that expresses MPO in the absence of other myeloid markers. This group had an increased rate of relapse and a worse event-free survival than the patients with B-ALL who did not express MPO. © American Society for Clinical Pathology, 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  B-ALL; Mixed-phenotype acute leukemia; Myeloperoxidase

Mesh:

Substances:

Year:  2017        PMID: 28340210     DOI: 10.1093/ajcp/aqx021

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  MicroRNA-31 is a potential biomarker for screening B-lymphoblastic leukemia in children.

Authors:  Yan Zhang; Xin Li; Liping Bai; Li Li; Danhong Li; Xue Ding; Bo Wang; Chengwei Li
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 2.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

3.  Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.

Authors:  Etan Orgel; Thomas B Alexander; Brent L Wood; Samir B Kahwash; Meenakshi Devidas; Yunfeng Dai; Todd A Alonzo; Charles G Mullighan; Hiroto Inaba; Stephen P Hunger; Elizabeth A Raetz; Alan S Gamis; Karen R Rabin; Andrew J Carroll; Nyla A Heerema; Jason N Berman; William G Woods; Mignon L Loh; Patrick A Zweidler-McKay; John T Horan
Journal:  Cancer       Date:  2019-10-29       Impact factor: 6.860

Review 4.  Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment.

Authors:  Thomas B Alexander; Etan Orgel
Journal:  Curr Oncol Rep       Date:  2021-02-05       Impact factor: 5.075

5.  Isolated Myeloperoxidase Immunohistochemical Expression in Bone Marrow Biopsy Depicts Clinical Outcomes in Adults with Typical B-Acute Lymphoblastic Leukemia.

Authors:  Maha Mohamed Fawzy; Amal Abd El-hafez; Shaimaa El-Ashwah; Tarek E. Abouzeid; Maryan Fahmi Waheeb; Maha Saif; Metwaly Ibrahim Mortada; Mayada A. Ghannam; Heba Sheta
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.